BDTX
Black Diamond Therapeutics Inc
Stock NASDAQ – Stock Market Prices, News & Analysis
Black Diamond Therapeutics is a biotechnology company that develops targeted therapies for cancer.
Black Diamond Therapeutics Inc
BDTX
Black Diamond Therapeutics is a biotechnology company that develops targeted therapies for cancer.
Price history of Black Diamond Therapeutics Inc
Price history of Black Diamond Therapeutics Inc
Performance & Momentum
Black Diamond Jumps on Silevertinib Progress
Black Diamond Therapeutics is seeing renewed interest after Wedbush raised its price target to $14 from $13 and reiterated an Outperform rating. The move reflects progress in silevertinib, the company’s lead drug candidate, which remains central to the stock’s valuation. The company also confirmed that its phase 2 clinical data, expected in the second quarter of 2026, remain on track, with cash seen as sufficient through the second half of 2028. Although quarterly losses persist, the company’s clinical and financial visibility is improving, which could support the stock in the near term.
Strategic Analysis
Black Diamond Therapeutics Inc • 2026
Black Diamond Therapeutics is an oncology biotech specializing in the development of targeted therapies for hard-to-treat cancers. Its positioning is based on a niche, high-scientific-leverage approach, centered on the clinical value creation of its lead candidate and its ability to turn development data into a stock catalyst.
- Focused scientific positioning in precision oncology, a segment with strong value-creation potential
- Recent momentum supported by progress on silevertinib, which is improving the clinical visibility of the flagship program
- Historical ability to generate sharp rebounds when development milestones are achieved
- High dependence on a still-limited and not very diversified development pipeline, with significant binary risk
- Speculative biotech profile, sensitive to clinical and regulatory disappointments as well as financing needs
Momentum is improving sharply and fits into a favorable medium-term trend, driven by market interest in progress on silevertinib. Recent news is acting as a confidence catalyst for the story, but the move remains typical of a development-stage biotech: strong when clinical updates are positive, fragile without further confirmation. For retail investors, this points to an opportunistic profile rather than a stock with stable fundamental visibility.
Similar stocks to Black Diamond Therapeutics Inc
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
